Pharmesis International Balance Sheet Health
Financial Health criteria checks 3/6
Pharmesis International has a total shareholder equity of CN¥61.6M and total debt of CN¥15.0M, which brings its debt-to-equity ratio to 24.4%. Its total assets and total liabilities are CN¥115.8M and CN¥54.3M respectively. Pharmesis International's EBIT is CN¥2.0M making its interest coverage ratio 2.9. It has cash and short-term investments of CN¥4.6M.
Key information
24.36%
Debt to equity ratio
CN¥15.00m
Debt
| Interest coverage ratio | 2.9x |
| Cash | CN¥4.60m |
| Equity | CN¥61.57m |
| Total liabilities | CN¥54.27m |
| Total assets | CN¥115.85m |
Recent financial health updates
Pharmesis International (SGX:BFK) Takes On Some Risk With Its Use Of Debt
Mar 03
Is Pharmesis International (SGX:BFK) Using Too Much Debt?
Oct 10Would Pharmesis International (SGX:BFK) Be Better Off With Less Debt?
Dec 09Health Check: How Prudently Does Pharmesis International (SGX:BFK) Use Debt?
Jun 08Recent updates
Impressive Earnings May Not Tell The Whole Story For Pharmesis International (SGX:BFK)
Mar 07Pharmesis International (SGX:BFK) Takes On Some Risk With Its Use Of Debt
Mar 03Is Pharmesis International (SGX:BFK) Using Too Much Debt?
Oct 10Would Pharmesis International (SGX:BFK) Be Better Off With Less Debt?
Dec 09Health Check: How Prudently Does Pharmesis International (SGX:BFK) Use Debt?
Jun 08A Look At The Intrinsic Value Of Pharmesis International Ltd. (SGX:BFK)
Feb 23Financial Position Analysis
Short Term Liabilities: BFK's short term assets (CN¥56.5M) exceed its short term liabilities (CN¥53.6M).
Long Term Liabilities: BFK's short term assets (CN¥56.5M) exceed its long term liabilities (CN¥692.0K).
Debt to Equity History and Analysis
Debt Level: BFK's net debt to equity ratio (16.9%) is considered satisfactory.
Reducing Debt: BFK's debt to equity ratio has increased from 23.4% to 24.4% over the past 5 years.
Debt Coverage: BFK's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: BFK's interest payments on its debt are not well covered by EBIT (2.9x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/14 10:46 |
| End of Day Share Price | 2025/05/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharmesis International Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.